Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 16/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29685925 | 1.00 | PDE2A (0.66) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL30557838 | 1.00 | PDE2A (0.66) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL14120778 | 1.00 | PDE2A (0.66) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL4233776 | 1.00 | PDE2A (0.66) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| Hydrochloric Acid SCHEMBL2715888 | 0.98 | PDE2A (0.64) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL16043553 | 0.87 | PDE2A (0.51) | PDE2A | |
| SCHEMBL16044616 | 0.87 | PDE2A (0.51) | PDE2AHTR2AHTR2CHTR2B | |
| SCHEMBL16868139 | 0.85 | PDE2A (0.50) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL20811529 | 0.85 | PDE2A (0.67) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL22221342 | 0.85 | PDE2A (0.67) | PDE2AHTR2AHTR2CHTR2BIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4469438-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4265599-A1 | PYRIMIDINE CARBOXAMIDE COMPOUND AND USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| CN-112062730-B | 4-oxo-3, 4-dihydro-1, 2, 3-benzotriazines as modulators of GPR139 | 武田药品工业株式会社 | 2023-09-29 | — | — | CN | disclosed |
| CN-116783191-A | Tricyclic carboxamide derivatives as PRMT5 inhibitors | 美国安进公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| CN-113710667-A | Fused cyclic pyrimidinone derivatives for the treatment of HBV infection or HBV induced diseases | 爱尔兰詹森科学公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-3270926-B1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2021-08-04 | — | — | EP | disclosed |
| CN-112062730-A | 4-oxo-3, 4-dihydro-1, 2, 3-benzotriazines as modulators of GPR139 | 武田药品工业株式会社 | 2020-12-11 | — | — | CN | disclosed |
| US-6335350-B1 | VARICELLA-ZOSTER, HUMAN CYTOMEGALO, EPSTEIN-BARR AND KAPOSI HERPESVIRUS TREATMENT | AMERICAN HOME PRODUCTS CORPORATION | 2002-01-01 | — | — | US | disclosed |
| EP-1137633-A2 | ACETAMIDE AND SUBSTITUTED ACETAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-04 | — | — | EP | disclosed |
| US-6271236-B1 | PHENYL UREAS/THIOUREAS AS INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE ENZYME, USEFUL IN TREATING HUMAN CYTOMEGALOVIRUS, HERPES SIMPLEX VIRUSES, EPSTEIN-BARR VIRUS, AND VARICELLA-ZOSTER VIRUS | WYETH | 2001-08-07 | — | — | US | disclosed |
| US-6262082-B1 | Diaminopyridine-containing thiourea inhibitors of herpes viruses | WYETH | 2001-07-17 | — | — | US | disclosed |
| US-6262090-B1 | Aminopyridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6207715-B1 | USEFUL IN THERAPY OF DISEASES ASSOCIATED WITH HERPES VIRUSES INCLUDING HUMAN CYTOMEGALOVIRUS, HERPES SIMPLEX VIRUSES, EPSTEIN-BARR VIRUS, VARICELLA-ZOSTER VIRUS, HUMAN HERPESVIRUSES-6 AND -7, AND KAPOSI HERPES VIRUS | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-27 | — | — | US | disclosed |
| US-6201013-B1 | INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH) INHIBITOR; SIDE EFFECT REDUCTION, NON-DRUG RESISTANT | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-13 | — | — | US | disclosed |
| US-6197803-B1 | VIRICIDES; PREVENTION REPRODUCTION | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-06 | — | — | US | disclosed |
| US-6166028-A | Diaminopuridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000034237-A2 | ACETAMIDE AND SUBSTITUTED ACETAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | CNKSR1, UGT1A1, REV1 | PDE2A 333/4885HTR2A 1255/4885HTR2C 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.